Exscientia, a clinical-stage Artificial Intelligence (AI)-driven pharmatech company, today announced that it has won the Queen’s Award for Enterprise in Innovation, recognising its pioneering work in the field of AI-driven drug discovery.
Her Majesty the Queen has acknowledged the success of Exscientia’sAI-driven drug discovery platform, repeatedly taking new molecules from discovery to the clinic with unprecedented efficiency and with discovery times consistently under 12 months. Established in 2012, Exscientia is based in Oxford and Dundee with more than 125 employees across the UK, US and Japan.
Professor Andrew Hopkins, CEO and Founder of Exscientia, said “We are honoured to receive this Queen’s Award. It recognises the great strides that Exscientia is making in the AI-led drug discovery field. Our technology has resulted in the world’s first ever drugs designed using AI to enter Phase 1 testing for the treatment of OCD in collaboration with Sumitomo Dainippon and for immuno-oncology in partnership with Evotec. Winning this award is testament to the hard work, dedication and passion of our team, and I am delighted to accept it on their behalf.”
Now in its 55th year, the Queen’s Awards for Enterprise is the most prestigious business award in the country, with winning businesses able to use the esteemed Queen’s Awards Emblem